| Pharmaceutical Information |
| Drug Name |
Palifermin |
| Drug ID |
BADD_D01655 |
| Description |
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.[L17933] |
| Indications and Usage |
For treatment of oral mucositis associated with chemotherapy and radiation therapy. |
| Marketing Status |
approved |
| ATC Code |
V03AF08 |
| DrugBank ID |
DB00039
|
| KEGG ID |
D05338
|
| MeSH ID |
D051523
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0O7GU
|
| NDC Product Code |
66658-112 |
| UNII |
QMS40680K6
|
| Synonyms |
Fibroblast Growth Factor 7 | Keratinocyte Growth Factor | Palifermin |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
162394-19-6 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
